deltatrials
Completed PHASE3 NCT00597584

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin

Sponsor: Affymax

Conditions Anemia Chronic Kidney Disease Chronic Renal Failure
Interventions Epoetin alfa or Epoetin beta peginesatide
Updated 7 times since 2017 Last updated: Mar 6, 2013 Started: Oct 31, 2007 Primary completion: Jul 31, 2009 Completion: Jan 31, 2010

Listed as NCT00597584, this PHASE3 trial focuses on Anemia and Chronic Kidney Disease and remains completed. Sponsored by Affymax, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affymax
  • Takeda
Data source: Affymax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain, Amiens, France, Arlington, United States, Asheville, United States, Bakersfield, United States, Barcelona, Spain, Bordeaux, France, Bremen, Germany, Brookhaven, United States, Brooklyn, United States and 61 more location s